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Objectives: To describe medication use patterns and adherence rates for 
schizophrenia patients after initiating antipsychotic treatment in Tianjin, 
China. MethOds: Data were extracted from the Tianjin Urban Employee Basic 
Medical Insurance database (2008-2010). Adult patients with a schizophrenia 
diagnosis, newly initiating or restarting antipsychotics (no antipsychotics during 
previous 90 days) with 12-month continuous enrollment after their first observed 
antipsychotic prescription were included. Patients’ medication prescribing patterns 
and antipsychotic adherence are described. Results: A total of 1216 patients were 
identified, with a mean (SD) age of 51.43 (12.48) years, 54.11% female. 83.14% of 
patients initiated with one antipsychotic and 16.86% with ≥ 2 antipsychotics. 37.99% 
of patients were initiated on typical antipsychotics, 52.06% on atypicals, and 9.95% 
on both. A higher portion of typical initiators were co-prescribed antianxiety and 
anticholinergic medications than atypical starters (both p< 0.001). During the follow-
ing 12 months, the majority of patients remained on medications from their initial 
antipsychotic class (80.74% of typical initiators vs. 86.41% of atypical initiators) or 
the same medication (66.45% of typical initiators vs. 70.93% of atypical initiators). 
More typical initiators switched to, or augmented with, atypical antipsychotics than 
atypical initiators to/with typical antipsychotics (19.26% vs. 13.59%, P= 0.011). During 
the following 3, 6 and 12 months, antipsychotic continuation rates (≤ 30 days gap) 
were 50.33%, 23.60%, and 8.88%, respectively. Medication Possession Ratios were low, 
with means (SD) of 0.58 (0.32), 0.44 (0.30), and 0.34 (0.27) for the 3, 6 and 12 months, 
respectively. cOnclusiOns: More individuals with schizophrenia were treated 
with atypicals rather than typical antipsychotics. The majority of patients tended 
to stay with one antipsychotic drug class or the same medication. Patients’ adher-
ence to prescribed antipsychotics was low. This study highlights the importance 
of selecting an effective medication when starting antipsychotic therapy in China. 
However much could be done to improve treatment adherence.
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Objectives: 1) To determine the minimal important change (MID) of indirect util-
ity score for patients with osteoarthritis (OA) over 3-year follow up, and 2)Estimate 
the impact of comorbidity for patients reaching the MID. MethOds: A total of 878 
patients with symptomatic knee or/and hip OA of KHOALA cohort were included. 
Comorbidity were assessed by Functional Comorbidity Index (FCI). Utility score 
was assessed using SF-6D, and limitation in activities by WOMAC function score 
(0-100,0 is better), at baseline and 3-year. The MID of utility was assessed using 
standard error of measurement (SEM). According to MID, patients were classified as 
negative/positive change or unchanged. Two separate multinomial logistic models 
were fitted to determine predictors of positive or negative change over the MID 
threshold. Both models included sociodemographic characteristics and the mean 
difference of WOMAC score between baseline and 3-year. Results: A total of 650 
OA patients completed the questionnaire at both times. The mean (SD) utility was 
0.664 (±0.110) at baseline and 0.667 (±0.110) at 3-year. Patients have on average 2.5 
(±1.94) comorbidities and a signifcant (p< .0001) decrease of the WOMAC function 
score at 3-year. The MID of SF-6D utility score was 0.067: 147 patients classified with 
negative and 156 with a positive change. In the first model including the number 
of comorbidities, patients with a decrease of the WOMAC function score had an 
increased utility (OR= 0.95; p< .0001). In the second model, patients with pneumo-
logic (OR= 1.88; p= 0.03) or neurologic (OR= 2.73;p= 0.047) disease were likely to have 
improved utility, while patients having a psychiatric disease were less likely to have 
an improvement (OR= 0.54;p= 0.029). cOnclusiOns: According to MID, about half 
of patients had a positive or negative change in their utility score. Compared to 
functional severity of OA, comorbidities have a relatively marginal impact on indi-
rect utility score. This suggests that clinically, considering the functional severity 
of OA remains a first priority.
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Objectives: Rheumatoid arthritis (RA) is a chronic, systemic disease associated 
with comorbidities and extra-articular manifestations (EAM) . The main objective 
of the study was to estimate the frequency and impact of comorbidities and EAM in 
well-defined RA patients. MethOds: A prospective study was conducted at a ter-
tiary care hospital between the years 2009 & 2012. Patients (age ≥ 18 years) with RA, 
fulfilling the revised criteria of the American college of rheumatology (1987 & 2010), 
were enrolled in the study. Standard clinical, laboratory and radiological measures 
of RA and details of comorbidities and EAM were recorded using patient hospital 
records. Results: Of 602 RA patients, 481 (79.9%) females and 121 (20.1%) males 
were present. Mean age of 47.57±12.78 years, mean disease duration of 4.52±4.75 
was conducted. Family impact was assessed as: Financial burden, Employment 
Burden, and Time-related burden. Binary and multinomial logistic regressions 
were conducted to compare likelihood of adverse family impact across ASD, DD 
without ASD, MHC without ASD, and DD and MHC without ASD, after adjust-
ing for socio-demographics, number of special children in the household, child’s 
functional ability, and presence of a physical condition. Results: Majority of 
the sample were older children (6-17 years), Whites, caregivers with ≥ 200% FPL 
income and greater than high school education. Sixteen percent (n= 2,801) of the 
caregivers had a child with an ASD diagnosis. Caregivers of children with ASD 
were more likely to have financial burden than caregivers of children with DD 
(AOR= 1.45, 95% CI= 1.10-1.91) and MHC (AOR= 1.59, 95% CI= 1.33-1.91). There were 
no significant differences in financial burden reports between caregivers of chil-
dren with ASD and those with both DD and MHC. Caregivers of children with ASD 
were also more likely to leave a job (employment), as compared to caregivers of 
children with DD (AOR= 1.57, 95% CI= 1.23-2.00), MHC (AOR= 3.06, 95% CI= 2.51-3.74), 
or both (AOR= 1.73, 95% CI= 1.36-2.20). Caregivers of children with ASD were more 
likely to report time-related burden as compared to caregivers of children with 
MHC (AOR= 2.87, 95% CI= 2.18-3.78) and DD and MHC (AOR= 1.80, 95% CI= 1.32-
2.44). cOnclusiOns: Caregivers of children with ASD are more likely to report 
an adverse family impact as compared to caregivers of children with DD, MHC, 
or both.
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Objectives: With increasing prevalence of dementia worldwide the interest in the 
dementia burden and impact on the health care system is rising. Yet comprehensive 
information about long-term needs and patterns of care of dementia patients and 
informal caregivers is scarce. Dementia specific registries provide an opportunity 
to investigate these aspects by long-term-data analysis. However, so far no inter-
national standards exist for developing a dementia registry. MethOds: An inter-
disciplinary team (psychiatry, public health, psychology, medical sociology, health 
economics and gerontology) established a registry structure in 2012. In the concep-
tion phase, existing registries, studies of dementia and best practice scenarios were 
identified. Features were combined in our concept and inclusion criteria, time for 
follow-up, fields of particular relevance and instruments were determined. A ques-
tionnaire was built and tested in exemplar sites. Results: The pilot study started 
with prospective interviews in January 2013 to evaluate the concept. The inclusion 
criterion is a dementia diagnosis according to ICD-10. Patients are recruited from 
the regional memory clinic during the process of diagnosis. Patient drop outs occur 
after initial inclusion because of other ensured diagnosis such as depression. Both 
patients and caregivers are interviewed separately with internationally approved 
valid instruments. The follow-up will take place after 6, 12 months and annually 
until death or loss to follow-up. cOnclusiOns: Existing dementia registries are 
very rare and heterogeneous in their structure, with currently no standards on 
quality indicators and processes. However, the complexity of dementia requires a 
sophisticated organizational structure for covering all aspects of dementia. Despite 
the challenges, our dementia registry structure provides essential, comprehensive 
and long-term information about the dementia care setting. The research is funded 
by the European Commission, ICT FP7, project ID 287509.
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Objectives: There is an increasing demand for medication reviews to improve 
the quality of prescribing for patients with chronic illness such as psychiatric 
patients. Traditionally, this has been undertaken by physicians. Pharmacists have 
also proven to be a resource in this field but registered nurses are the health profes-
sionals spending most time directly with the patient and very few studies inves-
tigate nurses’ role and potential in improving the appropriateness of medication. 
Therefore, the objective of this study is to investigate the effect of educating nurses 
in general pharmacology and conducting systematic medication reviews using 
computer based screening. The effect is evaluated in a controlled interventional 
study. MethOds: An interventional study including 2 acute psychiatric wards. In 
one ward nurses’ will receive pharmacological training and the other ward will func-
tion as a control. The nurses will perform approximately 250 medication reviews 
followed by medication reviews performed by pharmacologists. Primary outcomes 
are the respective frequencies, types and severity of potential inappropriate pre-
scriptions identified by the nurses and pharmacologists and an estimation of the 
interratervariability between the two professions. Results: The hypothesis is that 
nurse-led medication reviews will reduce potential inappropriate prescribing and 
that training will increase nurses’ ability to identify and report potential inappropri-
ate prescribing. It is assumed that this intervention, in addition to a more appropri-
ate prescribing, will lead to a reduction in length of hospitalization for psychiatric 
patients. cOnclusiOns: The perspective for this study is to add knowledge about 
frequency, types and potential severity of potential inappropriate prescribing for 
psychiatric patients. The study will contribute with information regarding the effect 
of pharmacological training of nurses and possibly improve medication safety for 
psychiatric patients. Results from this study could serve as evidence, when hospital 
management makes decisions on how to accede the need for medication reviews 
as part of an ongoing accreditation process.
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with first oBP prescription (index event) between January 2004–December 2007, 
≥ 50 years of age, with no history of cancer and a minimum of 12 months’ data 
before and 6 months’ after the index event. Follow-up for any osteoporotic frac-
ture was until December 2008. Persistence was defined as duration of continuous 
oBP use with no gaps > 3 months; compliance was assessed using the medica-
tion possession ratio (MPR; proportion of time with treatment available). HRU 
was evaluated using total primary care contact (including prescriptions), and all 
specialist referrals and hospitalisations. Analyses were stratified by persistence 
and compliance. Results: A total of 21,717 patients were included (mean age, 
73.5 years). Between 2004–2007, fracture rates per patient–year were: 0.14 (95% CI: 
0.12, 0.16; group with MPR < 80%) and 0.11 (0.10, 0.12; MPR ≥ 80%) for patients with 
12–24 months’ persistence vs 0.09 (0.08, 0.10) and 0.07 (0.06, 0.08), respectively, 
for patients with ≥ 36 months’ persistence. Hospitalisation rates were 0.38 (0.34, 
0.42; MPR < 80%) and 0.30 (0.29, 0.32; MPR ≥ 80%) for patients with 12–24 months’ 
persistence vs 0.55 (0.52, 0.59) and 0.18 (0.17, 0.19), respectively, for patients with 
≥ 36 months’ persistence. Among patients who discontinued oBPs and had < 12 
months’ persistence and MPR ≥ 80% before discontinuation, fracture rates were 
0.02 (0.01, 0.03) and 0.09 (0.07, 0.12) in the first and second 6 months following 
discontinuation, respectively, and hospitalisation rates were 0.09 (0.07, 0.11) and 
0.48 (0.42, 0.55), respectively. cOnclusiOns: Outcomes associated with oBPs were 
improved with longer persistence and higher compliance. However, in patients 
with < 12 months’ persistence, protection against fractures and hospitalisation 
diminished 6 months after discontinuation of oBPs.
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Objectives: The AMPLE trial concluded comparable efficacy of adalimumab (ADA) 
and abatacept (ABA) after one-year methotrexate (MTX) combination treatment for 
rheumatoid arthritis (RA). This study compared effects of adalimumab v. abatacept, 
each in MTX combination, on progressive RA joint damage, adjusting for study 
population characteristics. MethOds: Two placebo-controlled trials in early RA, 
PREMIER (ADA+MTX v. MTX) and AGREE (ABA+MTX v. MTX) were selected based on 
design and comparability of enrollment criteria. Patient-level data from PREMIER 
were adjusted, using propensity score weighting, to match average baseline char-
acteristics from AGREE, including RA duration and clinical measures. Radiographic 
progression (RP) was a change in total Sharp score (TSS) > 0 (modified TSS in 
PREMIER and Genant-modified TSS in AGREE). Joint space narrowing (JSN) and joint 
erosion (JE) scores in PREMIER were scaled to proportion with AGREE measures. 
After re-weighting, one-year incremental effects were compared for ADA+MTX vs. 
ABA+MTX, including RP rates, mean JSN and JE score changes from baseline, disease 
activity score (DAS28) remission rates, and American College of Rheumatology 50% 
improvement (ACR50). Results: Compared to AGREE patients, PREMIER patients 
were slightly older, more likely to be Caucasian, had longer RA duration, higher 
C-reactive protein levels, more severe joint damage, and lower functional impair-
ment at baseline. After re-weighting, more ADA+MTX patients had no RP after one 
year compared to ABA+MTX patients (27.0% v. 8.3%; p= 0.02). Mean improvements in 
JSN (-1.41 v. -0.04) and JE (-1.54 v. -0.39) scores from baseline were numerically greater 
with ADA+MTX; statistical significance could not be assessed as standard errors 
were not published for AGREE. No statistically significant differences were observed 
in DAS28 remission rates (p= 0.47) and ACR50 responses (p= 0.72). cOnclusiOns: 
Although both combination therapies yielded similar disease activity measures at 
one year in early RA patients, ADA+MTX offered greater protection against radio-
graphically-confirmed joint damage than ABA+MTX.
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Objectives: Psoriatic arthritis (PA) is an inflammatory disease affecting joints and 
connective tissues. The anti-tumor necrosis factor (TNF) biologics are increasingly 
being used in patients who have failed traditional disease-modifying antirheu-
matic drugs. Etanercept has shown efficacy in treatment of PA. The objective of 
this study was to conduct meta-analysis and present total evidence for etanercept 
in treatment of PA. MethOds: For this meta-analysis we included randomized 
controlled trials (RCTs)evaluating etanercept for the treatment of PS. RCTs study-
ing adult populations with active and progressive PA with an inadequate response 
to previous DMARD therapy were eligible. Trials conducted among PA populations 
with prior experience with anti-TNF agents, including an inadequate response, 
were excluded. A systematic literature search for Etanercept trials was undertaken 
for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was 
collected for the study size, interventions, year, and the three outcomes HAQ, PASI 
and PsARC. For meta-analysis, random effects and fixed effects models were used 
to obtain cumulative statistics. Results: Two RCTs with a total of 131 patients 
were identified. The pooled response rates for Etanercept for PsARC were 75% (95% 
CI 60%-90%), for HAQ were 59% (95% CI 46%-72%), and for PASI were 24% (95% CI 
13%-34%). The pooled response rates for placebo for PsARC were 30% (95% CI 26%-
35%), for HAQ were 5% (95% CI 1%-9%), and for PASI were 3% (95% CI 0%-7%). For 
PsARC the cumulative relative risk with Etanercept versus placebo was 0.40 (95% 
CI 33%-48%). For HAQ, the cumulative relative risk with placebo versus Etanercept 
was 0.08 (95% CI 5%-12%). For PASI, the cumulative relative risk with placebo ver-
sus Etanercept was 0.14 (95% CI 8%-20%). cOnclusiOns: Meta-analysis shows 
Etanercept offers patients with psoriatic arthritis an effective therapeutic option 
for control of their disease.
years and mean days of hospitalization 6.44±4.47 were observed. Disease duration 
of more than 2 years was observed in 336 (55.8%) patients. RA alone, RA with 1 
comorbidity, RA with 2 comorbidities, RA with 3 comorbidities, RA with 4 comorbidi-
ties, RA with 5 comorbidities, were present in 227 (37.7%), 171 (28.4%), 118 (19.6%), 
58 (9.6%), 19 (3.2%), 9 (1.5%) patients respectively. The most common comorbidities 
were diabetes mellitus 114 (18.94%), hypertension 104 (17.28%) and EAM was anemia 
351 (58.30%). cOnclusiOns: Comorbidities and EAM were present in substantial 
proportion of RA patients. Diabetes mellitus, hypertension and anemia were found 
to be most common in our setting. Early diagnosis and management are necessary 
to reduce their impact on therapeutic outcomes in RA.
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Objectives: To determine the impact of comorbidity burden on real-world health 
care costs of rheumatoid arthritis (RA) patients in Turkey, using nationwide real-
world data. MethOds: Study data was obtained from MEDULA (2009-2011). Using 
International Classification of Disease Tenth Revision Clinical Modification (ICD-
10-CM) codes, adult RA patients (ages 18-99) were identified for the identification 
period (June 1, 2010 - December 31, 2010). Patients were required to have two RA 
diagnoses at least 60 days apart, and were grouped as prevalent and incident cases. 
The date of the first RA claim was identified for each patient and designated as 
the index date. Total health care costs were examined over the 12-month period 
following the index date. To control for clinical characteristics, a comorbidity 
index score for each patient during the baseline period was calculated using the 
Elixhauser method. This index is the sum of a comprehensive set of 30 present 
comorbid conditions, and is widely-used in the outcomes research field to deter-
mine patient health status. Individual comorbidities, such as diabetes, respira-
tory diseases, allergy and cardiovascular diseases, were identified using ICD-10 
codes. Results: A total of 2,613 patients met all inclusion criteria (693 incident; 
1,920 prevalent patients). Prevalent patients had higher comorbidity index scores 
relative to incident patients. Nearly 35% of incident and 40% of prevalent patients 
had at least one cardiovascular, diabetic, respiratory, or allergy comorbid condi-
tion prior to the diagnosis. The mean Elixhauser Comorbidity Index score was 
calculated as 5.31 for incident and 5.7 for prevalent patients. Prevalent patients 
with respiratory and cardiovascular comorbid conditions incurred additional 
health care costs of € 302 and € 283 respectively. For incident patients, respiratory 
comorbid conditions increased the health care costs with € 916. cOnclusiOns: 
Respiratory comorbid conditions were associated with health care costs for both 
prevalent and incident RA patients in Turkey.
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Objectives: To apply a previously validated claims-based severity index for rheu-
matoid arthritis (SIFRA) to prevalent rheumatoid arthritis (RA) groups in Turkey 
and assess the effect of claims-based RA severity on health care costs and bio-
logic use. MethOds: The Turkish national health insurance database MEDULA 
(01JUN2009-31DEC2011) was used for the study. Prevalent RA patients were required to 
be age 18-99 with two RA diagnoses ≥ 60 days apart and continuous enrollment 1 year 
pre- (baseline period) and post-index date (follow-up), which was the first RA claim 
during the identification period (01JUN2010-31DEC2010). SIFRA was calculated for the 
baseline period. For the follow-up period, total health care costs and biologic use were 
examined. To determine health care costs, generalized linear models were applied, 
and multivariate logistic regression determined the effect of SIFRA on outcome meas-
ures for biologic use. Results: A total of 1,920 RA patients were identified. The mean 
SIFRA score was 14.21. There was a significant variation in scores across cities. Study 
results confirmed increased biologic use in more severe patients. After adjusting for 
differences in age, gender, region and comorbidity index, patients in the high SIFRA 
tercile were 5.16 times more likely to be prescribed biologics (p< 0.001, confidence 
interval [CI]: 3.46-7.69), and incurred more annual health care costs in the amount of 
€ 2,091 (p< 0.001, CI: € 1,557-€ 2,625) than those in the low SIFRA tercile. cOnclusiOns: 
This study showed that RA severity is a significant determinant of health care costs 
and biologic therapy use. Biologic use was positively correlated with the severity score. 
According to severity scores, the total medical costs of RA patients in Turkey ranged 
from € 1,435 to € 3,275. Since statistically omitting a variable from population models 
provides biased and inconsistent estimates, any comparative effectiveness studies 
on RA treatment should include severity scores in the analysis.
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Objectives: To assess the impact of persistence and compliance on fracture 
rates and health care resource use (HRU) in women treated with oral bispho-
sphonates (oBPs). MethOds: This analysis of the UK CPRD included women 
